IWM
TRDA icon

IHT Wealth Management’s Entrada Therapeutics TRDA Stock Holding History

IHT Wealth Management’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Hold
11,100
– – ﹤0.01% 1214
2025
Q4 		$114K Hold
11,100
– – ﹤0.01% 1152
2025
Q3 		$64.4K Buy
11,100
+400
+4% +$2.34K ﹤0.01% 1150
2025
Q2 		$71.9K Buy
+10,700
New +$86.1K ﹤0.01% 1126

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IHT Wealth Management's TRDA Position: Q1 2026 in Review

IHT Wealth Management held its Entrada Therapeutics (TRDA) position steady in Q1 2026 at 11,100 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

IHT Wealth Management first reported a position in TRDA in Q2 2025 and has held it in 4 quarters since. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • IHT Wealth Management held 11,100 shares of Entrada Therapeutics worth $140K as of Q1 2026.
  • IHT Wealth Management left its Entrada Therapeutics share count unchanged in Q1 2026.
  • Entrada Therapeutics made up ﹤0.01% of IHT Wealth Management's portfolio in Q1 2026, its #1214 holding.
  • IHT Wealth Management first reported a position in Entrada Therapeutics in Q2 2025 and has held it in 4 quarters since.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on IHT Wealth Management's 13F filing for Q1 2026, filed 15 May 2026.